| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Guidelines for the use and interpretation of assays for monitoring autophagy.
|
Autophagy
|
2012
|
20.08
|
|
2
|
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
|
N Engl J Med
|
2003
|
8.93
|
|
3
|
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
|
Lancet
|
2010
|
5.04
|
|
4
|
Genetics and cytogenetics of multiple myeloma: a workshop report.
|
Cancer Res
|
2004
|
4.54
|
|
5
|
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
|
J Clin Oncol
|
2013
|
3.75
|
|
6
|
The genetic architecture of multiple myeloma.
|
Nat Rev Cancer
|
2012
|
3.71
|
|
7
|
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
|
Blood
|
2011
|
2.69
|
|
8
|
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.
|
Blood
|
2006
|
2.43
|
|
9
|
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.
|
Blood
|
2007
|
2.38
|
|
10
|
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.
|
Blood
|
2012
|
2.38
|
|
11
|
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.
|
Blood
|
2010
|
2.25
|
|
12
|
Antimyeloma activity of heat shock protein-90 inhibition.
|
Blood
|
2005
|
2.24
|
|
13
|
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
|
Blood
|
2007
|
1.93
|
|
14
|
The impact of extramedullary disease at presentation on the outcome of myeloma.
|
Leuk Lymphoma
|
2009
|
1.77
|
|
15
|
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
|
Lancet Oncol
|
2011
|
1.71
|
|
16
|
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
|
Cancer Res
|
2007
|
1.70
|
|
17
|
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.
|
Blood
|
2010
|
1.67
|
|
18
|
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
|
J Clin Oncol
|
2011
|
1.66
|
|
19
|
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response.
|
EMBO J
|
2011
|
1.65
|
|
20
|
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
|
Radiology
|
2014
|
1.64
|
|
21
|
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma.
|
Leuk Lymphoma
|
2010
|
1.58
|
|
22
|
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
|
Blood
|
2002
|
1.51
|
|
23
|
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.
|
Leuk Lymphoma
|
2006
|
1.49
|
|
24
|
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
|
Blood
|
2008
|
1.45
|
|
25
|
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
|
Clin Cancer Res
|
2011
|
1.44
|
|
26
|
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.
|
Clin Cancer Res
|
2010
|
1.39
|
|
27
|
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
|
Blood
|
2010
|
1.36
|
|
28
|
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.
|
Blood
|
2013
|
1.35
|
|
29
|
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
|
Blood
|
2011
|
1.32
|
|
30
|
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
|
Haematologica
|
2011
|
1.32
|
|
31
|
Untangling the unfolded protein response.
|
Cell Cycle
|
2008
|
1.32
|
|
32
|
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
|
Blood
|
2002
|
1.22
|
|
33
|
Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma.
|
Ther Clin Risk Manag
|
2006
|
1.20
|
|
34
|
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.
|
J Clin Oncol
|
2011
|
1.20
|
|
35
|
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
|
Haematologica
|
2008
|
1.20
|
|
36
|
Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
|
Clin Cancer Res
|
2008
|
1.19
|
|
37
|
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.
|
J Biol Chem
|
2002
|
1.18
|
|
38
|
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.
|
Blood
|
2013
|
1.16
|
|
39
|
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.
|
Clin Cancer Res
|
2013
|
1.11
|
|
40
|
Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma.
|
Br J Haematol
|
2002
|
1.09
|
|
41
|
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
|
Blood
|
2003
|
1.09
|
|
42
|
Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma.
|
Cancer Lett
|
2006
|
1.07
|
|
43
|
DangER: protein ovERload. Targeting protein degradation to treat myeloma.
|
Haematologica
|
2012
|
1.06
|
|
44
|
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.
|
Blood
|
2003
|
1.05
|
|
45
|
The potential role of epigenetic therapy in multiple myeloma.
|
Br J Haematol
|
2009
|
1.04
|
|
46
|
The role of second autografts in the management of myeloma at first relapse.
|
Haematologica
|
2006
|
1.03
|
|
47
|
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
|
Genes Chromosomes Cancer
|
2011
|
1.02
|
|
48
|
Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.
|
J Natl Cancer Inst
|
2014
|
1.01
|
|
49
|
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
|
Haematologica
|
2007
|
1.00
|
|
50
|
Aminopeptidase inhibition as a targeted treatment strategy in myeloma.
|
Mol Cancer Ther
|
2009
|
0.99
|
|
51
|
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
|
Lancet Oncol
|
2003
|
0.98
|
|
52
|
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
|
Clin Cancer Res
|
2004
|
0.97
|
|
53
|
Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.97
|
|
54
|
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
|
Blood
|
2012
|
0.96
|
|
55
|
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.
|
Blood
|
2004
|
0.96
|
|
56
|
Heat shock proteins in multiple myeloma.
|
Oncotarget
|
2014
|
0.95
|
|
57
|
Improved risk stratification in myeloma using a microRNA-based classifier.
|
Br J Haematol
|
2013
|
0.95
|
|
58
|
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
|
Br J Haematol
|
2004
|
0.95
|
|
59
|
Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.
|
Blood
|
2014
|
0.94
|
|
60
|
Advances in oral therapy for multiple myeloma.
|
Lancet Oncol
|
2006
|
0.94
|
|
61
|
Haplotypes in the tumour necrosis factor region and myeloma.
|
Br J Haematol
|
2005
|
0.94
|
|
62
|
Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress.
|
Cancer Lett
|
2013
|
0.93
|
|
63
|
A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.
|
Clin Cancer Res
|
2011
|
0.93
|
|
64
|
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
|
Br J Haematol
|
2007
|
0.92
|
|
65
|
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.
|
PLoS One
|
2013
|
0.91
|
|
66
|
Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma.
|
Br J Haematol
|
2011
|
0.91
|
|
67
|
Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.
|
Biol Blood Marrow Transplant
|
2011
|
0.91
|
|
68
|
High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD.
|
Clin Transplant
|
2012
|
0.89
|
|
69
|
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
|
Br J Haematol
|
2010
|
0.89
|
|
70
|
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study.
|
Support Care Cancer
|
2014
|
0.88
|
|
71
|
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
|
Health Qual Life Outcomes
|
2014
|
0.88
|
|
72
|
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.
|
Genes Chromosomes Cancer
|
2014
|
0.87
|
|
73
|
Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma.
|
Br J Haematol
|
2007
|
0.87
|
|
74
|
Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
|
Br J Haematol
|
2005
|
0.87
|
|
75
|
Role of thalidomide in the treatment of patients with multiple myeloma.
|
Crit Rev Oncol Hematol
|
2013
|
0.83
|
|
76
|
Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells.
|
J Immunol Methods
|
2008
|
0.82
|
|
77
|
Proteasome inhibition and multiple myeloma.
|
Curr Opin Investig Drugs
|
2007
|
0.81
|
|
78
|
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.
|
Leuk Lymphoma
|
2013
|
0.81
|
|
79
|
A stressful life (or death): combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability.
|
Oncotarget
|
2011
|
0.81
|
|
80
|
Identification of autophosphorylation inhibitors of the inositol-requiring enzyme 1 alpha (IRE1α) by high-throughput screening using a DELFIA assay.
|
J Biomol Screen
|
2012
|
0.80
|
|
81
|
An update on drug combinations for treatment of myeloma.
|
Expert Opin Investig Drugs
|
2008
|
0.80
|
|
82
|
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
|
Haematologica
|
2006
|
0.79
|
|
83
|
Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
|
Eur J Haematol
|
2008
|
0.79
|
|
84
|
Inhibiting the molecular evolution of cancer through HSP90.
|
Oncotarget
|
2012
|
0.79
|
|
85
|
Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma.
|
Br J Haematol
|
2010
|
0.79
|
|
86
|
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism.
|
Oncogene
|
2003
|
0.78
|
|
87
|
Current and potential epigenetic targets in multiple myeloma.
|
Epigenomics
|
2014
|
0.78
|
|
88
|
Understanding the molecular biology of myeloma and its therapeutic implications.
|
Expert Rev Hematol
|
2012
|
0.77
|
|
89
|
The impact of response on bone-directed therapy in patients with multiple myeloma.
|
Blood
|
2013
|
0.77
|
|
90
|
Novel drugs in myeloma: harnessing tumour biology to treat myeloma.
|
Recent Results Cancer Res
|
2011
|
0.77
|
|
91
|
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
|
Br J Haematol
|
2014
|
0.76
|
|
92
|
Starving to succeed.
|
Autophagy
|
2009
|
0.76
|
|
93
|
A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
94
|
Understanding the multiple biological aspects leading to myeloma.
|
Haematologica
|
2014
|
0.76
|
|
95
|
The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells.
|
Blood
|
2005
|
0.76
|
|
96
|
Reply to M. Roschewski et al.
|
J Clin Oncol
|
2014
|
0.75
|
|
97
|
An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
98
|
Cyclooxygenase-2 (COX-2) in multiple myeloma: prognostic factor or therapeutic target?
|
Br J Haematol
|
2007
|
0.75
|
|
99
|
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
|
Br J Haematol
|
2013
|
0.75
|
|
100
|
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
|
Leuk Lymphoma
|
2014
|
0.75
|